17. Quality issues in cord blood banking  by McCullough, J.
improve patient outcomes. Over the past 18 months, the commit-
tee established common standards for donor recruitment and
screening, cord blood collection, testing, processing, cryopreser-
vation and storage. Eligible cord blood units are listed on the
NMDP donor registry which provides search management, patient
advocacy, conﬁrmatory typing and donor reservations. The Reg-
istry also facilitates distribution of the cord blood units to the
transplant centers, acquires post transplant follow-up data and
provides this data back to the banks for their internal quality
assurance and regulatory reporting requirements. The NMDP also
holds contracts with over 150 transplant centers performing unre-
lated donor transplants, oversees quality and manages billing for
donor procurement. The initial goals of the NMDP banking pro-
gram were to standardize banking practices among member banks.
Five subcommittees were established to address Collections, Qual-
ity Standards, Research, IS/IT, Research and Economies. These
committees established uniform standards for donor selection, col-
lection, processing, testing and banking; criteria for assessing con-
genital anomalies and infant health; an inter-bank proﬁciency pro-
gram; an eye-friendly search report through TRANS Link and
cord blood unit report through CORD Link; improved data out-
comes reporting system and incorporated FDA requirements for
eligibility determination and cGTPs into screening documentation
and labeling. A preliminary research agenda was also developed. A
commitment to apply for mandatory accreditation by 12/05 was
adopted by all member banks. Criteria were established for a cord
blood unit to qualify for listing in the NMDP registry and included
a minimum total nucleated cell count of 9 108 cells with minimal
post processing viability of 90%, enumeration of NRBC and CD34
content, negative bacterial cultures, CFU growth, high resolution
HLA typing for DRB1, testing for hemoglobinopathies and a
minimum of 2 attached segments on the bag in which the unit was
cryopreserved. Collection criteria were standardized to exclude
multiple births; gestational age 34 weeks; a history of cancer,
immune or blood disorders in a ﬁrst degree relative; and the
presence of congenital anomalies associated with congenital blood
disorders on the newborn physical examination. The NMDP in-
ventory now contains approximately 40,000 cord blood units.
Thirty-six percent of the donors represent ethnic minority back-
grounds. Approximately 500 units have been shipped for transplant
to date. Current barriers to collection and banking were reviewed
with their potential solutions. In conclusion, the NMDP banking
network functions as a program within the NMDP employing
common standards for cord blood donors, collection, processing
and storage listing on a single registry in combination with volun-
teer adult donors. Oversight is provided by HRSA. The recent
afﬁliation with the CIBMTR will enable the research agenda.
Efforts over the next years will focus on increasing collections,
establishing protocols for clinical research and obtaining accredi-
tation for all participating banks.
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As the frequency of umbilical cord blood (UCB) stem cell trans-
plantation has increased, the quality of UCB available in banks is
an important part of the success of the transplants. The AABB and
the Foundation for Accreditation of Cellular Therapy (FACT-
NETCORD) have promulgated standards and regulations pertain-
ing to collection, testing, processing, and banking of UCB for
transplantation. These standards are founded upon quality system
essentials very similar to that of the current Good Manufacturing
Practices (GMPs) and GTPs promulgated by the FDA. For the
most part, the requirements of the standards are similar and pro-
vide a basis for consistency of UCB bank operations. However,
there are some differences that would allow UCB units to be
determined suitable for transplantation in some banks but not
others depending on the source of standards used by that bank.
Also, the requirements have changed over time and so some units
that were suitable for banking at one time may not meet more
contemporary requirements. We used a quality assurance moni-
toring system to evaluate UCB units provided to us for transplant
by UCB banks in the United States and Europe. Of 268 units of
UCB shipped to us for transplantation during a three year period,
151 (56%) had one or more issues potentially related to quality that
required evaluation before a ﬁnal decision regarding their suitabil-
ity for use. There were a total of 246 speciﬁc issues in the 151 units.
The issues involved quality control (54%), medical history (40%),
and labels and documentation (6%). Risks to patients from these
issues were arbitrarily judged to be likely in 10%, potential in 35%,
and unlikely in 55%. The 10% of issues thought likely to affect the
quality of the unit were primarily due to quality control issue such
as transmissible disease test results, potential bacterial contamina-
tion, storage conditions during shipping, and processing methods.
Some of these quality issues such as units with incomplete or
positive tests for transmissible diseases, misleading statements
about the status of testing, tests not done on proper blood samples,
improper UCB unit labels, records and documents lacking proper
unique identifying numbers, or important data related to the UCB
and positive bacterial culture results are examples of failure to use
or follow clear expectations of quality assurance programs. Some of
these units should never have been placed in the useable inventory,
which suggests that despite available standards, some UCB banks
are not operating in conformance with published standards. Con-
siderable variation can also occur even when banks follow applica-
ble standards and quality control programs. This is due to four
factors. First, there are some differences between standards (AABB
and FACT-NETCORD) that would allow UCB units to be de-
termined suitable for transplantation by some banks but not others
depending on which set of standards is being followed. Secondly,
standards and regulations promulgated by AABB, FACT-NET-
CORD, and FDA are not speciﬁc and therefore leave it to the
bank’s discretion to establish criteria for donor acceptance and
quality control test results. Thirdly, standards have changed over
time such that units placed appropriately into the bank in the past
may not meet contemporary standards. Fourthly, each bank may
decide to place individual units into their useable inventory despite
failure to meet that bank’s own criteria as long as the medical
director takes responsibility and documents the reason for deviat-
ing from the banks standard procedures or policies. If standards are
established to assure quality, these four factors mean that different
units within a UCB bank or units from different banks may have
different degrees of quality and, thus, presumably safety. Our
ﬁndings indicate that despite quality programs for UCB promul-
gated by the AABB and FACT-NETCORD, there is considerable
variation in how banks select, process, and control the quality of
units they place into the bank. Some CBUs in banks’ inventory
available for patients do not meet AABB/FACT-NETCORD stan-
dards. Some standards are not speciﬁc and there is a lack of
consensus about a number of issues related to quality. Communi-
cation between banks and transplant centers may not sufﬁciently
timely or effective to allow thoughtful decision-making regarding
the suitability of a speciﬁc CBU for a speciﬁc patient. Our expe-
rience indicates that it is likely that some UCB units presently
being searched in banks in the United States and Europe may not
meet current requirements and/or our desired levels of quality.
Effective and timely communication between the UCB and the
transplant center clinical cell engineering laboratory and transplant
team is essential; present interactions between the banks and trans-
plant centers may not be effective in identifying units that might
pose extra risks and require more unique decision-making. Decisions
about the use of particular units should involve both the transplant
physicians and physicians with expertise in donor suitability.
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A COMPARISON OF PRE- AND POST-CRYOPRESERVATION CD34
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The identiﬁcation of CB units with maximum engraftment po-
tential is an essential issue in CB transplantation. University of
Minnesota (UM) data have shown a high probability of survival in
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